Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus

2015 ◽  
Vol 56 (2) ◽  
pp. 231-238 ◽  
Author(s):  
Jianguo Zhi ◽  
Suoping Zhai
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Plasma Glucose ◽  
Glucokinase Activator ◽  
Postprandial Plasma Glucose

THE ASSOCIATION OF DECREASED SERUM GDNF LEVEL WITH HYPERGLYCEMIA AND DEPRESSION IN TYPE 2 DIABETES MELLITUS

2019 ◽  
Vol 25 (9) ◽  
pp. 951-965 ◽  
Author(s):  
Yanxiaoxiao Yang ◽  
Bo Xie ◽  
Changping Ju ◽  
Hui Jin ◽  
Xiuli Ye ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Plasma Glucose ◽  
Density Lipoprotein ◽  
Normal Glucose Tolerance ◽  
Diabetes Distress ◽  
Postprandial Plasma Glucose ◽  
Distress Scale

Objective: Comorbidity of diabetes and depression is a critical problem. Decreased glial-derived neurotrophic factor (GDNF) has been demonstrated in depression, but no evidence of a relationship between GDNF and diabetes has been shown. The present studies were designed to investigate the relationship between GDNF and metabolism. Methods: In Study 1, we performed a case-control study in which subjects with type 2 diabetes mellitus (T2DM), prediabetes (p-DM), and normal glucose tolerance (NGT) were included. In Study 2, we performed a cross-sectional study in 296 patients having pre-existing diabetes in whom the levels of serum GDNF, blood glucose, blood lipids, blood pressure, body mass index, scores from the Patient Health Questionnaire (PHQ-9), the EuroQol-5 scale, and the diabetes distress scale were measured, as well as single-nucleotide polymorphisms of GDNF including rs884344, rs3812047, and rs2075680. Results: In Study 1, serum GDNF concentration was significantly lower in the T2DM group than in the NGT group (NGT: 11.706 ± 3.918 pg/mL; p-DM: 10.736 ± 3.722 pg/mL; type 2 diabetes mellitus [T2DM group]: 9.884 ± 2.804 pg/mL, P = .008). In Study 2, significantly decreased serum GDNF levels were observed in subjects with poor glycemic control or depression (glycated hemoglobin [HbA1c] <7.0% without depression: 11.524 ± 2.903 pg/mL; HbA1c ≥7.0% without depression: 10.625 ± 2.577 pg/mL; HbA1c <7.0% with depression: 10.355 ± 2.432 pg/mL; HbA1c ≥7.0% with depression: 8.824 ± 2.102 pg/mL, P = .008). Double-factor variance analysis showed that glycemic control and depression were independent factors for the GDNF level. Moreover, the serum GDNF level was significantly inversely associated with the fasting plasma glucose, 2 hours postprandial plasma glucose, HbA1c, and PHQ-9 score. Conclusion: Glycemic dysregulation was an independent factor for the GDNF level. These findings suggest that GDNF level might be involved in the pathophysiology of T2DM and depression through various pathways. Abbreviations: BP = blood pressure; CHO = cholesterol; DDS = diabetes distress scale; DM = diabetes mellitus; EQ-5D = the health-related dimensions of the EuroQol-5 scale; FPG = fasting plasma glucose; GDNF = glial-derived neurotrophic factor; HbA1c = glycated hemoglobin; HDL = high-density lipoprotein; LDL = low-density lipoprotein; NGT = normal glucose tolerance; PHQ-9 = Patient Health Questionnaire; p-DM = prediabetes; PPG = postprandial plasma glucose; SNP = single-nucleotide polymorphism; T2DM = type 2 diabetes mellitus; TG = triglyceride

scholarly journals EFFECT OF SITAGLIPTIN ON GLYCEMIC CONTROL AND BEYOND - IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

2018 ◽  
Vol 11 (8) ◽  
pp. 316
Author(s):  
Ramya Ravichandar ◽  
Aravind Anapathoor Nagarajan
Keyword(s):  
Diabetes Mellitus ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Lipid Profile ◽  
Plasma Glucose ◽  
Fasting Blood Glucose ◽  
Postprandial Plasma Glucose

Objective: The objective of the study was to assess the pleiotropic effects of Sitagliptin as add-on therapy to the conventional antidiabetic drugs.Methods: This was designed as a prospective study. 140 patients with type 2 diabetes mellitus (T2DM) whose glycated hemoglobin (HbA1c) was >7% despite receiving education on diet and exercise and/or medications were enrolled in this study. Sitagliptin (100 mg) was administered once a day orally for 6 months as an add-on therapy with the conventional antidiabetic drugs. The outcome of the therapy was assessed on the level of improvement in the fasting plasma glucose, postprandial plasma glucose, HbA1c levels, lipid profile, body mass index, blood pressure, and albuminuria in the third and 6th month when compared to the first visit.Results: After 6 months of treatment with Sitagliptin, fasting blood glucose levels significantly reduced (202.6±49.21 to 186.1±50.14, p=0.029) as well as HbA1c (9.5±1.27 to 9.1±1.28, p=0.016). There was a statistically significant (p<0.001) reduction of blood pressure, cholesterol, and urinary albumin-creatinine ratio progressively.Conclusion: Sitagliptin has a significant effect on lipid profile, blood pressure and albuminuria in addition to its effect on blood glucose profile and HbA1c without many side effects, in patients with T2DM.

Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin

2013 ◽  
Vol 15 (8) ◽  
pp. 750-759 ◽  
Author(s):  
J. P. H. Wilding ◽  
M. Leonsson-Zachrisson ◽  
C. Wessman ◽  
E. Johnsson
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glucokinase Activator ◽  
Dose Ranging
Sign in / Sign up

Export Citation Format

Share Document